Pharminent

Eli Lilly, Boehringer Launch Long-Acting Basal Insulin in U.S.

NewsBASAGLAR will be available by prescription from retail and mail order pharmacies across the U.S. Topics: Drug Pipeline http://www.dddmag.com/news/2016/12/eli-lilly-boehringer-launch-long-acting-basal-insulin-us

Filed under: Diabetes, Insulin

FDA approves Companion’s Bluetooth-enabled insulin pen backed by Lilly

http://www.fiercepharma.com/drug-delivery/fda-approves-companion-s-bluetooth-enabled-insulin-pen-backed-by-lilly

Filed under: Diabetes, Insulin

MannKind maps out Afrezza strategy

After Sanofi broke off its partnership, Mannkind has scaled up to meet the demands of marketing Afrezza by itself. But a turnaround is going to take more than just resources.  http://www.biopharmadive.com/news/mannkind-maps-out-afrezza-strategy/424216/

Filed under: Diabetes, Insulin

InPen: A Smart Insulin Pen That Calculates Dosage, Tracks Injections, Companion Medical Study

http://www.biospace.com/news_story.aspx?StoryID=428182&full=1

Filed under: Diabetes, Insulin

Novo Nordisk’s touch screen insulin pump given green light by EMA

mylife YpsoPump approved for use with pump
cartridge NovoRapid PumpCart http://www.pmlive.com/pharma_news/novo_nordisks_touch_screen_insulin_pump_given_green_light_by_ema_1052688

Filed under: Diabetes, Insulin

J&J preparing to launch a new mealtime insulin delivery patch

http://www.bizjournals.com/philadelphia/morning_roundup/2016/06/jnj-johnson-onetouch-via-insulin-patch-diabetes.html

Filed under: Diabetes, Insulin

Successful Switch to Sanofi’s Toujeo® Evaluated in a Real-World Setting

[CNW Group] – Successful Switch to Sanofi’s Toujeo® Evaluated in a Real-World Setting http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/successful-switch-sanofis-toujeo-evaluated-150100108.html

Filed under: Diabetes, Insulin

MannKind Regains Afrezza® Marketing Rights

[GlobeNewswire] – VALENCIA, Calif., April 05, 2016– MannKind Corporation has assumed responsibility for the worldwide development and commercialization of Afrezza ® Inhalation Powder from Sanofi, effective today, in a … http://finance.yahoo.com/news/mannkind-regains-afrezza-marketing-rights-130000930.html

Filed under: Diabetes, Insulin

FDA Accepts Sanofi New Drug Application for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

PARIS, Feb. 22, 2016 /PRNewswire/ — Sanofi announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for… http://www.prnewswire.com/news-releases/fda-accepts-sanofi-new-drug-application-for-once-daily-fixed-ratio-combination-of-insulin-glargine-and-lixisenatide-300223605.html

Filed under: Diabetes, Insulin

Tresiba safer than insulin glargine, says Novo Nordisk

Trial compares its basal insulin with Sanofi’s Lantus http://www.pmlive.com/pharma_news/tresiba_safer_than_insulin_glargine,_says_novo_nordisk_920070

Filed under: Diabetes, Insulin

FDA Approves First U-500 Insulin Pen Device

Eli Lilly’s Humulin R U-500 KwikPen (insulin human injection) 500 units/m eliminates the need for dose conversions. FDA Approvals http://www.medscape.com/viewarticle/857811?src=rss

Filed under: Diabetes, Insulin

ORIGINALE Published: Insulin Glargine Neutral on CVD, Cancer

The results of the follow-on trial to ORIGIN have been published and reassure that insulin glargine has neutral effects on cardiovascular outcomes and cancer in patients with dysglycemia or diabetes. Medscape Medical News http://www.medscape.com/viewarticle/856884?src=rss

Filed under: Diabetes, Insulin

MannKind CFO: We’re searching for a new Afrezza marketing partner after Sanofi’s departure

Matthew Pfeffer asserted to investors on a call that Sanofi’s termination of the licensing deal would not be “the end of the line" for either Afrezza or MannKind.  http://www.biopharmadive.com/news/mannkind-cfo-were-searching-for-a-new-afrezza-marketing-partner-after-san/411621/

Filed under: Diabetes, Insulin

Sanofi abandons inhaled insulin pact with Mannkind

Poor sales prompt return of Afrezza rights less than a year after its launch http://www.pmlive.com/pharma_news/sanofi_abandons_inhaled_insulin_pact_with_mannkind_899999

Filed under: Diabetes, Insulin

Poor sales prompt Sanofi to pull plug on Mannkind inhaled insulin

LONDON (Reuters) – French drugmaker Sanofi is to stop selling an inhalable insulin developed by Mannkind, following disappointing sales of the product since its launch in February 2015.

http://www.reuters.com/article/us-sanofi-mannkind-idUSKBN0UJ1KO20160105?feedType=RSS&feedName=healthNews

Filed under: Diabetes, Insulin

Sanofi Submits NDA for Once-Daily Fixed Ratio Combination of Insulin Glargine, Lixisenatide

​Sanofi announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational fixed-ratio combination of insulin glargine 100 Units/mL and lixisenatide, which if approved would be administered as a single daily injection for the treatment of adults with type 2 diabetes. http://www.dddmag.com/news/2015/12/sanofi-submits-nda-once-daily-fixed-ratio-combination-insulin-glargine-lixisenatide

Filed under: Diabetes, Insulin

Sanofi Submits New Drug Application for the Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

http://cws.huginonline.com/S/152918/PR/201512/1975672_5.html

Filed under: Diabetes, Insulin

Lilly’s Lantus biosimilar approved in the US

Basaglar is first insulin product to be licensed via the FDA’s biosimilar pathway http://www.pmlive.com/pharma_news/lillys_lantus_biosimilar_approved_in_the_us_889067

Filed under: Diabetes, Insulin

FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes

The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm477734.htm

Filed under: Diabetes, Insulin

Patients Can Buy Insulin Without a Prescription, But Should They?

Versions sold that way are based on older formulas and make tight control of blood sugar harder. But they are cheaper and might save the life of a diabetic patient whose alternative is to go without. Kaiser Health News http://www.medscape.com/viewarticle/856013?src=rss

Filed under: Diabetes, Insulin

Categories